Cargando…

CAAP48, a New Sepsis Biomarker, Induces Hepatic Dysfunction in an in vitro Liver-on-Chip Model

Sepsis is a leading cause of mortality in the critically ill, characterized by life-threatening organ dysfunctions due to dysregulation of the host response to infection. Using mass spectrometry, we identified a C-terminal fragment of alpha-1-antitrypsin, designated CAAP48, as a new sepsis biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaurock-Möller, Nancy, Gröger, Marko, Siwczak, Fatina, Dinger, Julia, Schmerler, Diana, Mosig, Alexander S., Kiehntopf, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401602/
https://www.ncbi.nlm.nih.gov/pubmed/30873161
http://dx.doi.org/10.3389/fimmu.2019.00273
_version_ 1783400176318152704
author Blaurock-Möller, Nancy
Gröger, Marko
Siwczak, Fatina
Dinger, Julia
Schmerler, Diana
Mosig, Alexander S.
Kiehntopf, Michael
author_facet Blaurock-Möller, Nancy
Gröger, Marko
Siwczak, Fatina
Dinger, Julia
Schmerler, Diana
Mosig, Alexander S.
Kiehntopf, Michael
author_sort Blaurock-Möller, Nancy
collection PubMed
description Sepsis is a leading cause of mortality in the critically ill, characterized by life-threatening organ dysfunctions due to dysregulation of the host response to infection. Using mass spectrometry, we identified a C-terminal fragment of alpha-1-antitrypsin, designated CAAP48, as a new sepsis biomarker that actively participates in the pathophysiology of sepsis. It is well-known that liver dysfunction is an early event in sepsis-associated multi-organ failure, thus we analyzed the pathophysiological function of CAAP48 in a microfluidic-supported in vitro liver-on-chip model. Hepatocytes were stimulated with synthetic CAAP48 and several control peptides. CAAP48-treatment resulted in an accumulation of the hepatocyte-specific intracellular enzymes aspartate- and alanine-transaminase and impaired the activity of the hepatic multidrug resistant-associated protein 2 and cytochrome P450 3A4. Moreover, CAAP48 reduced hepatic expression of the multidrug resistant-associated protein 2 and disrupted the endothelial structural integrity as demonstrated by reduced expression of VE-cadherin, F-actin and alteration of the tight junction protein zonula occludens-1, which resulted in a loss of the endothelial barrier function. Furthermore, CAAP48 induced the release of adhesion molecules and pro- and anti-inflammatory cytokines. Our results show that CAAP48 triggers inflammation-related endothelial barrier disruption as well as hepatocellular dysfunction in a liver-on-chip model emulating the pathophysiological conditions of inflammation. Besides its function as new sepsis biomarker, CAAP48 thus might play an important role in the development of liver dysfunction as a consequence of the dysregulated host immune-inflammatory response in sepsis.
format Online
Article
Text
id pubmed-6401602
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64016022019-03-14 CAAP48, a New Sepsis Biomarker, Induces Hepatic Dysfunction in an in vitro Liver-on-Chip Model Blaurock-Möller, Nancy Gröger, Marko Siwczak, Fatina Dinger, Julia Schmerler, Diana Mosig, Alexander S. Kiehntopf, Michael Front Immunol Immunology Sepsis is a leading cause of mortality in the critically ill, characterized by life-threatening organ dysfunctions due to dysregulation of the host response to infection. Using mass spectrometry, we identified a C-terminal fragment of alpha-1-antitrypsin, designated CAAP48, as a new sepsis biomarker that actively participates in the pathophysiology of sepsis. It is well-known that liver dysfunction is an early event in sepsis-associated multi-organ failure, thus we analyzed the pathophysiological function of CAAP48 in a microfluidic-supported in vitro liver-on-chip model. Hepatocytes were stimulated with synthetic CAAP48 and several control peptides. CAAP48-treatment resulted in an accumulation of the hepatocyte-specific intracellular enzymes aspartate- and alanine-transaminase and impaired the activity of the hepatic multidrug resistant-associated protein 2 and cytochrome P450 3A4. Moreover, CAAP48 reduced hepatic expression of the multidrug resistant-associated protein 2 and disrupted the endothelial structural integrity as demonstrated by reduced expression of VE-cadherin, F-actin and alteration of the tight junction protein zonula occludens-1, which resulted in a loss of the endothelial barrier function. Furthermore, CAAP48 induced the release of adhesion molecules and pro- and anti-inflammatory cytokines. Our results show that CAAP48 triggers inflammation-related endothelial barrier disruption as well as hepatocellular dysfunction in a liver-on-chip model emulating the pathophysiological conditions of inflammation. Besides its function as new sepsis biomarker, CAAP48 thus might play an important role in the development of liver dysfunction as a consequence of the dysregulated host immune-inflammatory response in sepsis. Frontiers Media S.A. 2019-02-25 /pmc/articles/PMC6401602/ /pubmed/30873161 http://dx.doi.org/10.3389/fimmu.2019.00273 Text en Copyright © 2019 Blaurock-Möller, Gröger, Siwczak, Dinger, Schmerler, Mosig and Kiehntopf. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Blaurock-Möller, Nancy
Gröger, Marko
Siwczak, Fatina
Dinger, Julia
Schmerler, Diana
Mosig, Alexander S.
Kiehntopf, Michael
CAAP48, a New Sepsis Biomarker, Induces Hepatic Dysfunction in an in vitro Liver-on-Chip Model
title CAAP48, a New Sepsis Biomarker, Induces Hepatic Dysfunction in an in vitro Liver-on-Chip Model
title_full CAAP48, a New Sepsis Biomarker, Induces Hepatic Dysfunction in an in vitro Liver-on-Chip Model
title_fullStr CAAP48, a New Sepsis Biomarker, Induces Hepatic Dysfunction in an in vitro Liver-on-Chip Model
title_full_unstemmed CAAP48, a New Sepsis Biomarker, Induces Hepatic Dysfunction in an in vitro Liver-on-Chip Model
title_short CAAP48, a New Sepsis Biomarker, Induces Hepatic Dysfunction in an in vitro Liver-on-Chip Model
title_sort caap48, a new sepsis biomarker, induces hepatic dysfunction in an in vitro liver-on-chip model
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401602/
https://www.ncbi.nlm.nih.gov/pubmed/30873161
http://dx.doi.org/10.3389/fimmu.2019.00273
work_keys_str_mv AT blaurockmollernancy caap48anewsepsisbiomarkerinduceshepaticdysfunctioninaninvitroliveronchipmodel
AT grogermarko caap48anewsepsisbiomarkerinduceshepaticdysfunctioninaninvitroliveronchipmodel
AT siwczakfatina caap48anewsepsisbiomarkerinduceshepaticdysfunctioninaninvitroliveronchipmodel
AT dingerjulia caap48anewsepsisbiomarkerinduceshepaticdysfunctioninaninvitroliveronchipmodel
AT schmerlerdiana caap48anewsepsisbiomarkerinduceshepaticdysfunctioninaninvitroliveronchipmodel
AT mosigalexanders caap48anewsepsisbiomarkerinduceshepaticdysfunctioninaninvitroliveronchipmodel
AT kiehntopfmichael caap48anewsepsisbiomarkerinduceshepaticdysfunctioninaninvitroliveronchipmodel